Healthcare Stocks

Eli Lilly and Novo Nordisk are the two defining companies in the modern incretin market. Both have powerful franchises in diabetes and obesity, both are spending heavily to expand supply, and both have late-stage candidates intended to extend their leadership. Yet their latest results describe very different operating trajectories. Lilly entered 2026 with accelerating tirzepatide … Read more

Last reviewed: September 11, 2026 Eli Lilly and Company (NYSE: LLY) is no longer merely a diversified pharmaceutical manufacturer with a promising diabetes medicine. Mounjaro and Zepbound have become a global growth engine, Lilly is investing tens of billions of dollars in manufacturing, and its cardiometabolic pipeline could broaden the franchise from injections into oral … Read more